Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
23. August 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 9046
Articles 1 - 20 / 180905
Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study From Vietnam.
Cancer Control
Nguyen H, Nguyen H, Nguyen HX, Truong M, Ngo T.
PMID: 42633534 [PubMed - indexed for MEDLINE]
Mitochondrial convergence of ferroptosis and cuproptosis in castration-resistant prostate cancer: From metabolic vulnerabilities to therapeutic targeting.
BBA Adv
Wang CL, Lv JT, Liu SJ, Zhang YY, Wang SL, Song SQ.
PMID: 42633322 [PubMed]
Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.
Urol Oncol
Teixeira EG, Torres LAF, Defante MLR, de Azevedo FM, Souza VC.
PMID: 42632294 [PubMed - as supplied by publisher]
A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis.
Urol Oncol
Shinohara M, Narita T, Hamaya T, Ichiyama T, Fujita N, Okamoto T, Yamamoto H, Ohyama C, Hatakeyama S.
PMID: 42632293 [PubMed - as supplied by publisher]
miR-638 Upregulation in Serum and Tissues Functions as a Diagnostic and Prognostic Biomarker and Facilitates Prostate Cancer Progression.
Urol Oncol
Wang L, Yang H, Wang J.
PMID: 42632292 [PubMed - as supplied by publisher]
Clinical characteristics, treatment patterns, and survival outcomes in ductal prostate cancer: a multicenter retrospective analysis.
World J Urol
Handke A, Paffenholz P, Schlack K, Seifert KE, Linxweiler J, Mink J, Flockerzi F, Nestler T, Wenzel M, Siech C, Darr C, Grünwald V, Roghmann F, Tully KH.
PMID: 42631874 [PubMed - indexed for MEDLINE]
The Intersection of Religiosity, Perceived Discrimination, and Psychological Well-Being in a Racially and Ethnically Diverse Sample of Male Cancer Survivors.
Cancer Control
Murphy A, Fletcher-Duncan A, Cherell CD, Li X, Fan W, Jacobs KL, Denis J, Lezama C, Bethune B, Hu B, Gonzalez BD, Green BL.
PMID: 42631521 [PubMed - indexed for MEDLINE]
Optimizing Sequential Decision Rules for Prostate Cancer Biopsy Management: A Multi-Objective Statistical Framework.
J Am Stat Assoc
Qiu J, Zhao YQ, Wei J, Chinnaiyan AM, Tosoian J, Zheng Y.
PMID: 42631260 [PubMed]
Mitochondrial Dysfunction in Renal Cell Carcinoma: A Comprehensive Review of Pathogenic Mechanisms and Emerging Therapeutic Opportunities.
Oncol Res
Wang Y, Liu J, Xu Q, Ma Z.
PMID: 42630702 [PubMed - indexed for MEDLINE]
Combining PSA density and imaging data with transcript markers from urinary cells to improve prediction of prostate cancer reclassification in patients on active surveillance.
BJUI Compass
Borkowetz A, Gräfe S, Kwe J, Fuessel S, Thomas C, Erdmann K.
PMID: 42630620 [PubMed]
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.
Ther Adv Med Oncol
Bimbatti D, Nasso C, Aspden D, Buti S, Antonj L, Signori A, Verzoni E, Lolli C, Di Napoli M, Fanelli M, De Lucia M, Masini C, Roviello G, Arduini D, Filippi R, Mennitto A, Sorarù M, Bozza G, Formisano L, Messina C, Bonomi L, Guida A, Fantinel E, Scagliarini S, Vitale MG, Chiellino S, Maiorano BA, Deppieri FM, Zucali PA, Cavo A, Caserta C, La Russa F, Conteduca V, Maines F, Zai S, Pierantoni F, Icardi M, Rescigno P, Di Costanzo F, Banna GL, Rebuzzi SE.
PMID: 42630506 [PubMed]
Efficacy of neoadjuvant novel hormonal therapy combined with radical prostatectomy for high-risk prostate cancer and analysis of biochemical recurrence-free survival.
Am J Transl Res
Jiang S, Du C, Qu L, Liu L, Ren B, Luo W.
PMID: 42630365 [PubMed]
The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.
Cancer Med
Nordheimer S, Gofrit ON.
PMID: 42630020 [PubMed - indexed for MEDLINE]
Prognostic and immunological value of LINC01615-related genes in kidney clear cell carcinoma: Integrated bioinformatics analysis and expression validation.
Medicine (Baltimore)
Guo S, Xu S, Song P, Fu J, Wang S, Xie W, Wang Y.
PMID: 42629666 [PubMed - indexed for MEDLINE]
Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404-12.
Eur Urol Oncol
Di Bello F, Gallioli A, Palou J, Breda A.
PMID: 42629309 [PubMed - as supplied by publisher]
Prospective Multicenter Study on the Predictive Role of Node-RADS Score in Patients With Prostate Cancer Who Are Candidates for Radical Prostatectomy: Comparative Analysis with Validated Nomograms and PET/CT Scan.
Eur Urol Focus
Sciarra A, Casale P, Bevilacqua G, Basile G, Santarelli V, Buffi NM, Lazzeri M, Lunghezzani G, Lucciola S, Messina E, Laschena L, Dehghanpour A, Di Pierro GB, Franco G, Del Giudice F, Gentilucci A, Dipinto P, Corvino R, Salciccia S, Magliocca FM, Panebianco V.
PMID: 42629306 [PubMed - as supplied by publisher]
No Evidence of Post-Finasteride Syndrome in 267,983 person-years follow-up in the Prostate Cancer Prevention Trial.
Urology
Till C, Tangen CM, Goodman P, Unger JM, Thompson IM Jr.
PMID: 42628582 [PubMed - as supplied by publisher]
Age at Diagnosis and Postoperative Outcomes Among Men Treated for Prostate Cancer in the U.S. Military Health System.
Clin Genitourin Cancer
Oroho MR, Dide-Agossou C, Kern SQ, Almeida AA, Darmon S, Shriver CD, Zhu K, Eaglehouse YL.
PMID: 42628214 [PubMed - as supplied by publisher]
APUC-6 Genes as a Potential Prognostic and Predictive Biomarker in the CHAARTED Prostate Cancer Trial.
JCO Precis Oncol
Shi X, Shetty AC, Wang J, Song Y, Sutera PA, Deek MP, Patel KR, Madan RA, Tang C, Proudfoot J, Davicioni E, Hussain A, Nguyen P, Sweeney C, Boytim E, Lacuna KP, Ryan CJ, Antonarakis ES, Tran PT, Hwang J.
PMID: 42628007 [PubMed - indexed for MEDLINE]
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.
Clin Cancer Res
Zacharias NM, Rupe ES, Chen X, Kotecha RR, Rieke DT, McGregor BA, Pesquera P, Yu Z, Grover A, Daw NC, Wang E, Chan SWS, Douglas-Lindsay D, Fan AC, Knoche EM, Kyriakopoulos CE, Lalani AA, Mantia CM, Merla A, Voss MH, Pfanzelter N, Ramakrishna S, Reaume NM, Tang T, Ingram DR, Shamsutdinova D, Wani KM, Wang WL, Lazar AJ, Sheth RA, Rao P, Grimm SL, Coarfa C, He R, Qian J, Duan F, Bisht D, Chauhan PK, Perelli L, Genovese G, Yang L, Lin C, Karam JA, La Posta L, Dondossola E, Basar R, Uprety N, Rezvani K, Gao J, Wang L, Solis Soto LM, Lim B, Tannir NM, Karki M, Msaouel P.
PMID: 42627757 [PubMed - as supplied by publisher]
Articles 1 - 20 / 180905
Page 1 of 9046
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy